Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 4/20 | 0.62 |
| ▸ | CA5A | P35218 | 4/20 | 0.62 |
| ▸ | CA7 | P43166 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA3 | P07451 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663606 | 0.87 | CA12 (0.69) | CA12CA9CA1CA4CA5A | |
| SCHEMBL27396152 | 0.85 | CA12 (0.68) | CA12CA9CA1CA4CA5A | |
| SCHEMBL28085698 | 0.82 | CA12 (0.64) | CA12CA9CA1CA4CA5A | |
| SCHEMBL13194963 | 0.81 | MAOB (0.65) | CA12CA9CA1CA4CA5A | |
| SCHEMBL7545069 | 0.81 | DRD4 (0.68) | CA12CA9CA1CA4CA5A | |
| SCHEMBL8750116 | 0.81 | CA12 (0.62) | CA12CA9CA1CA4CA5A | |
| SCHEMBL295803 | 0.81 | CA12 (0.77) | CA12CA9CA1CA4CA5A | |
| SCHEMBL3326190 | 0.81 | CA12 (0.77) | CA12CA9CA1CA4CA5A | |
| SCHEMBL29603488 | 0.81 | CA12 (0.77) | CA12CA9CA1CA4CA5A | |
| SCHEMBL4013360 | 0.81 | CA12 (0.62) | CA12CA9CA1CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119176798-A | Dihydropyrimidinone-coumarin derivative and preparation method thereof | 宜春学院 | 2024-12-24 | — | — | CN | claimed |
| CN-119060024-B | Aryl benzyl ether compound with affinity with monoamine oxidase B and application thereof | BEIJING NORMAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119176798-A | Dihydropyrimidinone-coumarin derivative and preparation method thereof | 宜春学院 | 2024-12-24 | — | — | CN | disclosed |
| CN-119060024-A | Aryl benzyl ether compound with affinity with monoamine oxidase B and application thereof | 北京师范大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-115894461-B | Novel coumarin-containing azole derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-115894461-A | Novel coumarin azole-containing derivative and preparation method and application thereof | 沈阳药科大学 | 2023-04-04 | — | — | CN | disclosed |
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
| CN-112218878-A | NTCP inhibitors | 北京生命科学研究所 | 2021-01-12 | — | — | CN | disclosed |
| CN-104968375-B | Photo-crosslinked hyaluronic acid derivative, and preparation method and application thereof | 菲迪亚制药股份公司 | 2018-03-13 | — | — | CN | disclosed |
| WO-1996028438-A1 | NON-NUCLEOSIDIC COUMARIN DERIVATIVES AS POLYNUCLEOTIDE-CROSS-LINKING AGENTS | NAXCOR (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0466773-B1 | COUMARIN DERIVATIVES FOR USE AS NUCLEOTIDE CROSSLINKING REAGENTS | NAXCOR (US) | 1996-06-12 | — | — | EP | disclosed |
| WO-1996010049-A1 | CUMARIN AND QUINOLINONE DERIVATIVES FOR PREPARING LIQUID CRYSTAL ORIENTATION LAYERS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-04-04 | — | — | WO | disclosed |
| EP-0693065-A4 | NON-NUCLEOSIDIC COUMARIN DERIVATIVES AS POLYNUCLEOTIDE-CROSSLINKING AGENTS | NAXCOR (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0693065-A1 | NON-NUCLEOSIDIC COUMARIN DERIVATIVES AS POLYNUCLEOTIDE-CROSSLINKING AGENTS | NAXCOR (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994024120-A1 | NON-NUCLEOSIDIC COUMARIN DERIVATIVES AS POLYNUCLEOTIDE-CROSSLINKING AGENTS | NAXCOR (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0466773-A4 | COUMARIN DERIVATIVES FOR USE AS NUCLEOTIDE CROSSLINKING REAGENTS | — | 1992-02-05 | — | — | EP | disclosed |
| EP-0466773-A1 | COUMARIN DERIVATIVES FOR USE AS NUCLEOTIDE CROSSLINKING REAGENTS. | NAXCOR (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082934-A | COUMARIN DERIVATIVES FOR USE AS NUCLEOTIDE CROSSLINKING REAGENTS | NAXCOR (US) | 1992-01-21 | — | — | US | disclosed |
| WO-1990012020-A1 | COUMARIN DERIVATIVES FOR USE AS NUCLEOTIDE CROSSLINKING REAGENTS | NAXCOR (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | CA12 4469/4885CA9 4038/4885CA1 4681/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | CA12 4469/4885CA9 4038/4885CA1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.